Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravesical bleomycin in bladder tumour prophylaxis.

M Tripi, C Pavone, P Ammatuna

    International Urology and Nephrology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Hierarchical dynamics and time-length scale superposition in glassy suspensions of ultra-low crosslinked microgels.

    The Journal of chemical physics·2026
    Same author

    Swelling-state-dependent structure of spread microgel monolayers.

    Journal of colloid and interface science·2026
    Same author

    Dispersions of weakly charged thermoresponsive microgels at high densities.

    Soft matter·2025
    Same author

    Micro PIXE mapping proves a differential distribution and concentration of trace elements in fungal structures of Rhizophagus intraradices.

    Fungal biology·2024
    Same author

    Fluid-solid transitions in photonic crystals of soft, thermoresponsive microgels.

    Soft matter·2023
    Same author

    The potential impact of acute coronary syndromes on automatic sensing system in Subcutaneous-ICDs.

    International journal of cardiology. Heart & vasculature·2021

    Intravesical bleomycin (BLM) did not effectively prevent superficial bladder tumor recurrences in high-risk patients. While well-tolerated locally with no systemic toxicity, the treatment failed to reduce tumor regrowth post-transurethral resection.

    Area of Science:

    • Urology
    • Oncology
    • Pharmacology

    Background:

    • Superficial bladder tumors frequently recur after endoscopic resection.
    • Intravesical therapies are used for prophylaxis, but efficacy varies.
    • Bleomycin (BLM) is a cytotoxic agent with potential for intravesical use.

    Purpose of the Study:

    • To evaluate the efficacy, tolerability, and systemic absorption of intravesical bleomycin for preventing superficial bladder tumor recurrences.
    • To assess bleomycin's effectiveness in high-risk patients post-transurethral resection (TUR).

    Main Methods:

    • Fifteen patients with recurrent superficial bladder tumors received intravesical bleomycin (30 mg in 30 ml saline) weekly for one month, then monthly for 12 months.
    • The instillate was retained in the bladder for 1 hour.

    Related Experiment Videos

  • Systemic absorption was assessed via microbiological assay of bleomycin in plasma and bladder perfusate.

    • Main Results:

    • Thirteen out of fifteen patients experienced tumor recurrences during treatment.
    • Four patients received a second course of treatment after repeat TUR, with three experiencing further recurrences.
    • Bleomycin was well-tolerated locally and showed no systemic toxicity. Measurable bleomycin levels were not detected in peripheral blood, despite significant amounts not being recovered from the bladder.

    Conclusions:

    • Intravesical bleomycin, administered as studied, was not effective in preventing superficial bladder tumor recurrences in high-risk patients.
    • The treatment demonstrated good local tolerability and a lack of systemic toxicity.
    • Further investigation into optimal dosing or patient selection may be warranted, though current findings suggest limited utility.